{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T04:35:23Z","timestamp":1791693323077,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009411","name":"Universit\u00e9 Paris-Est Cr\u00e9teil Val-de-Marne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.bcp.2018.12.007","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T10:32:14Z","timestamp":1544265134000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A new human pyridinium metabolite of furosemide, inhibitor of mitochondrial complex I, is a candidate inducer of neurodegeneration"],"prefix":"10.1016","volume":"160","author":[{"given":"C\u00e9line","family":"Laurenc\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narimane","family":"Zeghbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rivard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Lehri-Boufala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lachaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Barau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Le Corvoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Garrigue-Antar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2490-7585","authenticated-orcid":false,"given":"Christophe","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2018.12.007_b0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/01919510600985937","article-title":"Degradation of aqueous pharmaceuticals by ozonation and advanced oxidation processes: a review","volume":"28","author":"Ikehata","year":"2006","journal-title":"Ozone Sci. Eng."},{"issue":"2","key":"10.1016\/j.bcp.2018.12.007_b0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.toxlet.2007.10.012","article-title":"Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation","volume":"176","author":"Besse","year":"2008","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2018.12.007_b0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00613429","article-title":"On the fate of furosemide in man","volume":"9","author":"Beermann","year":"1975","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.12.007_b0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcp.2008.04.014","article-title":"In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway","volume":"76","author":"Kerdpin","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2018.12.007_b0025","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/(SICI)1099-081X(199712)18:9<753::AID-BDD63>3.0.CO;2-K","article-title":"Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum","volume":"18","author":"Lee","year":"1997","journal-title":"Biopharm. Drug Dispos."},{"issue":"5475","key":"10.1016\/j.bcp.2018.12.007_b0030","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/251508a0","article-title":"Hepatic necrosis caused by furosemide","volume":"251","author":"Mitchell","year":"1974","journal-title":"Nature (London)"},{"issue":"1","key":"10.1016\/j.bcp.2018.12.007_b0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-3565(25)30654-3","article-title":"Metabolic activation of furosemide to a chemically reactive, hepatotoxic metabolite","volume":"199","author":"Mitchell","year":"1976","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2018.12.007_b0040","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/jpet.107.125302","article-title":"The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore","volume":"322","author":"Williams","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2018.12.007_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2011.10.006","article-title":"Preparative access to transformation products (TPs) of furosemide: a versatile application of anodic oxidation","volume":"67","author":"Laurence","year":"2011","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bcp.2018.12.007_b0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chemosphere.2014.05.036","article-title":"Anticipating the fate and impact of organic environmental contaminants: a new approach applied to the pharmaceutical furosemide","volume":"113","author":"Laurence","year":"2014","journal-title":"Chemosphere"},{"issue":"22","key":"10.1016\/j.bcp.2018.12.007_b0055","doi-asserted-by":"crossref","first-page":"22691","DOI":"10.1007\/s11356-016-7398-2","article-title":"Microbial biotransformation of furosemide for environmental risk assessment: identification of metabolites and toxicological evaluation","volume":"23","author":"Olvera-Vargas","year":"2016","journal-title":"Environ. Sci. Pollut. Res. Int."},{"issue":"12","key":"10.1016\/j.bcp.2018.12.007_b0060","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1021\/tx700262z","article-title":"Chemical and enzymatic oxidation of furosemide: formation of pyridinium salts","volume":"20","author":"Chen","year":"2007","journal-title":"Chem. Res. Toxicol."},{"issue":"4587","key":"10.1016\/j.bcp.2018.12.007_b0065","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2018.12.007_b0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0006-291X(87)90689-9","article-title":"Inhibition of NADH oxidation by pyridine derivatives","volume":"146","author":"Ramsay","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2018.12.007_b0075","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/mds.20823","article-title":"Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?","volume":"21","author":"Tarsy","year":"2006","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.bcp.2018.12.007_b0080","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/cdd.2009.9","article-title":"Insights on a new path of pre-mitochondrial apoptosis regulation by a glycosaminoglycan mimetic","volume":"16","author":"Yue","year":"2009","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.bcp.2018.12.007_b0085","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0028-3908(03)00041-8","article-title":"Nicotine protects rat brain mitochondria against experimental injuries","volume":"44","author":"Cormier","year":"2003","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2018.12.007_b0090","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1248\/bpb.34.92","article-title":"Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL\/6 mice","volume":"34","author":"Inden","year":"2011","journal-title":"Biol. Pharm. Bull."},{"issue":"6","key":"10.1016\/j.bcp.2018.12.007_b0095","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s11064-015-1577-2","article-title":"Long-term systemic exposure to rotenone induces central and peripheral pathology of parkinson's disease in mice","volume":"40","author":"Murakami","year":"2015","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.bcp.2018.12.007_b0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1096\/fj.201600751r","article-title":"Neuroprotective effects of fingolimod in mouse models of Parkinson's disease","volume":"31","author":"Zhao","year":"2017","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.bcp.2018.12.007_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116641","article-title":"New roles of glycosaminoglycans in alpha-synuclein aggregation in a cellular model of Parkinson disease","volume":"10","author":"Lehri-Boufala","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bcp.2018.12.007_b0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.expneurol.2010.03.028","article-title":"Complex I: inhibitors, inhibition and neurodegeneration","volume":"224","author":"Schapira","year":"2010","journal-title":"Exp. Neurol."},{"issue":"11","key":"10.1016\/j.bcp.2018.12.007_b0115","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/0006-2952(95)02086-1","article-title":"Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"50","author":"McNaught","year":"1995","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2018.12.007_b0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.13234","article-title":"The phosphorylation of alpha-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease","volume":"135","author":"Xu","year":"2015","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.bcp.2018.12.007_b0125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0024-3205(96)00656-X","article-title":"Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem","volume":"60","author":"Eyles","year":"1997","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2018.12.007_b0130","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009316","article-title":"A guide to neurotoxic animal models of Parkinson's disease","volume":"1","author":"Tieu","year":"2011","journal-title":"Cold Spring Harbor Perspect. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2018.12.007_b0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jnc.13731","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"139","author":"Bose","year":"2016","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.bcp.2018.12.007_b0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00702-015-1386-4","article-title":"Mitochondrial mechanisms of redox cycling agents implicated in Parkinson's disease","volume":"123","author":"Lopert","year":"2016","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.bcp.2018.12.007_b0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fnana.2014.00155","article-title":"Parkinson's disease: animal models and dopaminergic cell vulnerability","volume":"8","author":"Blesa","year":"2014","journal-title":"Front. Neuroanat."},{"issue":"4","key":"10.1016\/j.bcp.2018.12.007_b0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tips.2009.12.006","article-title":"Lessons from the rotenone model of Parkinson's disease","volume":"31","author":"Greenamyre","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2018.12.007_b0155","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0304-3940(87)90366-1","article-title":"Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brains","volume":"81","author":"Mizuno","year":"1987","journal-title":"Neurosci. Lett."},{"issue":"8","key":"10.1016\/j.bcp.2018.12.007_b0160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0024-3205(87)90299-2","article-title":"MPTP, MPP+ and mitochondrial function","volume":"40","author":"Nicklas","year":"1987","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.bcp.2018.12.007_b0165","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0028-3908(98)00215-9","article-title":"Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation","volume":"38","author":"Balijepalli","year":"1999","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.bcp.2018.12.007_b0170","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1471-4159.2005.03416.x","article-title":"Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: role of granulocyte macrophage colony-stimulating factor","volume":"95","author":"Henze","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2018.12.007_b0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.fct.2016.08.009","article-title":"N-methyltetrahydropyridines and pyridinium cations as toxins and comparison with naturally-occurring alkaloids","volume":"97","author":"Herraiz","year":"2016","journal-title":"Food Chem. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2018.12.007_b0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0022-3565(25)30584-7","article-title":"Effects of ethacrynic acid and furosemide on isolated rat kidney mitochondria: inhibition of electron transport in the region of phosphorylation site II","volume":"198","author":"Manuel","year":"1976","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2018.12.007_b0185","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0024-3205(85)90060-8","article-title":"Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?","volume":"36","author":"Irwin","year":"1985","journal-title":"Life Sci."},{"issue":"18","key":"10.1016\/j.bcp.2018.12.007_b0190","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/0024-3205(88)90257-3","article-title":"Urinary excretion of MPTP and its primary metabolites in mice","volume":"43","author":"Lau","year":"1988","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.bcp.2018.12.007_b0195","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2967\/jnumed.116.189159","article-title":"Effect of MPTP on serotonergic neuronal systems and mitochondrial complex I activity in the living brain: a PET study on conscious rhesus monkeys","volume":"58","author":"Kanazawa","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"Pt 3","key":"10.1016\/j.bcp.2018.12.007_b0200","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1042\/bj20021594","article-title":"Mitochondrial threshold effects","volume":"370","author":"Rossignol","year":"2003","journal-title":"Biochem. J."},{"issue":"9","key":"10.1016\/j.bcp.2018.12.007_b0205","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tips.2009.06.005","article-title":"Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?","volume":"30","author":"Cicchetti","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2018.12.007_b0210","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"alpha-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"9996","key":"10.1016\/j.bcp.2018.12.007_b0215","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2018.12.007_b0220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E","article-title":"Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau","volume":"48","author":"Jicha","year":"1997","journal-title":"J. Neurosci. Res."},{"issue":"9","key":"10.1016\/j.bcp.2018.12.007_b0225","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218305069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218305069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:02:41Z","timestamp":1757768561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218305069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":45,"alternative-id":["S0006295218305069"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.12.007","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new human pyridinium metabolite of furosemide, inhibitor of mitochondrial complex I, is a candidate inducer of neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}